Dr. Horowitz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
75 Francis St
Brigham And Women's Hospital
Boston, MA 02115Phone+1 617-732-8843Fax+1 617-738-5124
Education & Training
- University of WashingtonResidency, Obstetrics and Gynecology, 1996 - 2000
- Duke University School of MedicineClass of 1996
Certifications & Licensure
- MA State Medical License 2003 - 2025
- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma Start of enrollment: 2006 Sep 01
- Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar Start of enrollment: 2006 Dec 01
- Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia Start of enrollment: 2012 Jun 18
- Join now to see all
Publications & Presentations
PubMed
- Ultra High-risk Gestational Trophoblastic Neoplasia.Kevin M Elias, Ross S Berkowitz, Neil S Horowitz
Hematology/oncology Clinics of North America. 2024-12-01 - 75 Years of Advancement in Gestational Trophoblastic Disease.Kevin M Elias, Antonio Braga, Neil S Horowitz, Ross S Berkowitz
Hematology/oncology Clinics of North America. 2024-12-01 - Diagnosis and Management of Molar Pregnancies.Antonio Braga, Gabriela Paiva, Marcio Barcellos, Kevin M Elias, Neil S Horowitz
Hematology/oncology Clinics of North America. 2024-12-01
Journal Articles
- Distinct microRNA Profiles for Complete Hydatidiform Moles at Risk for Malignant ProgressionNeil S Horowitz, Donald P Goldstein, Bradley J Quade, Ross S Berkowitz, Kevin M Elias, American Journal of Obstetrics and Gynecology
Press Mentions
- Gemcitabine plus Cisplatin and IMRT Produces Complete Responses in Vulvar CancerMarch 27th, 2023
- CRT Regimen Boosts Complete Response Rate in Unresectable Vulvar CancerMarch 27th, 2023
- More Than 110 Dana-Farber Affiliated Faculty Named as 2021 Top Doctors in Boston MagazineJanuary 5th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: